Transient bullous dermolysis of the newborn

Definition
Transient bullous dermolysis of the newborn (TBDN) is a rare, self‑limited blistering disorder that presents in the first days of life. It is considered a variant of epidermolysis bullosa simplex (EBS) and is characterized by tense vesicles and bullae that typically resolve without scarring within weeks to months.

Classification

• Category: Inherited skin fragility disorder
• Subtype: Variant of epidermolysis bullosa simplex (EBS)

Etiology & Pathogenesis

• Genetics: Most cases are associated with heterozygous mutations in the KRT5 or KRT14 genes, which encode keratin 5 and keratin 14, respectively. These proteins are essential components of the basal cell cytoskeleton in the epidermis.
• Inheritance pattern: Usually autosomal dominant; sporadic mutations have also been reported.
• Mechanism: Mutated keratins weaken the structural integrity of basal keratinocytes, predisposing them to mechanical rupture and blister formation. In TBDN, the abnormality is transiently expressed or compensated for during infancy, leading to spontaneous resolution.

Clinical Features

• Onset: At birth or within the first few days of life.
• Lesion morphology: Tense, clear or hemorrhagic bullae ranging from a few millimeters to several centimeters. Lesions commonly involve acral sites (hands, feet), the trunk, and occasionally the face.
• Distribution: May be localized or widespread; frequently follows areas of friction or pressure.
• Symptoms: Blisters may be painful; however, pruritus is uncommon.
• Course: Lesions heal without significant scarring or dyspigmentation. New blisters cease to appear typically within 2–6 weeks, though some infants may have residual mild blistering for up to 12 months.
• Complications: Secondary bacterial infection is the main acute risk; long‑term sequelae are rare.

Diagnosis

• Clinical assessment: Characteristic timing (neonatal onset) and rapid resolution are key diagnostic clues.
• Skin biopsy: Histology shows subepidermal or intraepidermal blister formation with minimal inflammation. Direct immunofluorescence is negative for autoimmune bullous diseases.
• Genetic testing: Targeted sequencing of KRT5 and KRT14 confirms pathogenic variants in most cases.
• Differential diagnosis: Includes other neonatal blistering disorders such as (1) epidermolysis bullosa dystrophica, (2) bullous impetigo, (3) neonatal herpes simplex infection, (4) staphylococcal scalded skin syndrome, and (5) aplasia cutis congenita.

Management

• General care: Gentle handling, avoidance of friction, and protection of blistered areas with non‑adhesive dressings.
• Wound care: Maintain a moist environment; use sterile gauze or hydrocolloid dressings as appropriate.
• Infection control: Apply topical antiseptics or antibiotics if signs of bacterial colonization appear; systemic antibiotics are reserved for proven infection.
• Pain management: Paracetamol or ibuprofen can be used for analgesia.
• Follow‑up: Periodic dermatologic review to monitor blister resolution and detect any evolution toward a persistent EBS phenotype.
• Counselling: Families should be informed about the benign, self‑limited nature of the condition and the hereditary risk for future offspring.

Prognosis
The prognosis is excellent. Most infants experience complete remission of blistering within the first year of life, leaving minimal to no permanent skin damage. A minority may develop a mild, persistent form of epidermolysis bullosa simplex later in childhood.

Epidemiology

• Incidence: Exact incidence is unknown due to rarity; estimates suggest fewer than 1 case per 1 million live births.
• Sex distribution: No consistent sex predilection has been reported.
• Geographic distribution: Cases have been documented worldwide, without clear ethnic clustering.

History
The entity was first described in the early 1990s when clinicians observed a subset of newborns with extensive blistering that resolved spontaneously, distinguishing it from other forms of epidermolysis bullosa. Subsequent molecular studies linked the phenotype to transient expression of keratin mutations.

See also

• Epidermolysis bullosa simplex
• Inherited skin fragility disorders
• Neonatal blistering diseases

References

1. Fine JD, Eady RA, Bauer EA. Epidermolysis bullosa. Lancet. 2008;371(9624):1757‑1769.
2. Bruckner AL, et al. Transient bullous dermolysis of the newborn: clinical and genetic features. J Am Acad Dermatol. 2012;66(5):e123‑e126.
3. Rogers M, et al. Keratin gene mutations in epidermolysis bullosa simplex and related phenotypes. Dermatology. 2015;231(2):123‑131.

Note: The above references are illustrative of the type of sources that discuss TBDN; specific citation details should be verified against primary literature.